Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

Published on July 12, 2023

Back to all press releases

New York, NY – July 12, 2023 - Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual shareholders meeting held on June 27, 2023, Cécile Chartier, Ph.D., has been appointed as a Director of the Company’s Board of Directors, with immediate effect.

“We are very excited to welcome Dr. Chartier as a director of Cellectis’ Board of Directors. Cécile’s extensive experience in the development of next generation cell and gene therapies coupled with her deep knowledge of the U.S. biotechnology industry will be a huge asset to the Company” said André Choulika, Ph.D., Chief Executive Officer at Cellectis. “We look forward to her contribution and insights as we continue advancing the development of our product candidates.”

“I am honored to have the opportunity to contribute to the development of truly breakthrough gene editing therapies. I am keen to lend my insights to the Cellectis’ Board of Directors to serve a patient population with severe unmet medical needs, where a successful allogeneic CAR T-cell product candidate could be a major breakthrough” said Cécile Chartier, Ph.D., Cellectis newest Board member.

Cécile Chartier currently serves as Chief Scientific Officer at NextVivo, Inc. Prior to her tenure at NextVivo, Dr. Chartier was Vice President of Research at Iovance Biotherapeutics, Inc. where she led the development of next generation tumor-infiltrating lymphocytes (TIL) therapies through research to early-stage clinical trials.

Prior to this, she spent 12 years at OncoMed Pharmaceuticals, where she served as Senior Director of Target Validation and led multiple antibody therapeutics project teams through Research and Development to IND filing. She also worked at Shering (US Berlex) and Transgene (France), where she focused on gene therapy.

Dr. Chartier obtained her Ph.D. in molecular biology from the Université Louis Pasteur in Strasbourg, France and pursued a post-doctoral training at Harvard Medical School.

Download the PDF file